Clinical Trial: A phase I, single center, open-label, non-randomized, single sequence, drug-drug interaction study to assess the effect of phenytoin (a CYP3A inducer) and clarithromycin (a CYP3A inhibitor) on the pharmacokinetics of a single dose of YMI024 in healthy participants (China)

China, Oct. 22 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A phase I, single center, open-label, non-randomized, single sequence, drug-drug interaction study to assess the effect of phenytoin (a CYP3A inducer) and clarithromycin (a CYP3A inhibitor) on the pharmacokinetics of a single dose of YMI024 in healthy participants'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134869

Registration Time: 2026/10/21

Type: Interventional study

Primary Sponsor: West China Hospital of Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348503

Published by HT Digital Content Services with permission from Heal...